Patent · US Active

Threo-DOPS controlled release formulation

US8460705B2 · kind B2 · utility

1Cited by
49References
44Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 13, 2012
Grant dateJun 11, 2013
Priority date
Expiry dateMar 13, 2032

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P29/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.